Related Experiment Video

Updated: Apr 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R Davies1, Nin Guan2, Armelle Logie3

  • 1Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, United Kingdom. barry.davies@astrazeneca.com.

Molecular Cancer Therapeutics
|September 10, 2015
PubMed

Insights

The AKT1(E17K) mutation drives tumor growth and is a target for AKT inhibitors. Clinical studies show these inhibitors can be effective, sometimes requiring combination therapy for optimal results in certain cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Activating mutations in AKT1, specifically AKT1(E17K), are found in various solid tumors.
  • While AKT1(E17K) transforms rodent cells, its oncogenic potential and therapeutic targeting in human cancers remain under investigation.
  • The efficacy of AKT inhibitors in human tumors harboring endogenous AKT1(E17K) mutations is not well-established.

Purpose of the Study:

  • To investigate the oncogenic role of AKT1(E17K) in breast epithelial cells.
  • To evaluate the therapeutic efficacy of AKT inhibitors against tumors with AKT1(E17K) mutations.
  • To explore the potential of combination therapies for tumors with co-occurring mutations.

Main Methods:

  • Exogenous expression of AKT1(E17K) in MCF10A cells to assess cellular transformation and in vivo tumor formation.
  • Treatment of breast cancer explants and MGH-U3 bladder cancer xenografts with AKT inhibitors (MK-2206, AZD5363) and/or FGFR inhibitor (AZD4547).
  • Analysis of a Phase I clinical study involving AZD5363 in cancer patients with AKT1(E17K) mutations.

Main Results:

  • Expression of AKT1(E17K) increased AKT phosphorylation, colony formation, and tumor growth in mice, effects reversed by AKT inhibitors.
  • Both allosteric and catalytic AKT inhibitors significantly inhibited growth in breast cancer models with AKT1(E17K).
  • Phase I study showed partial responses to AZD5363 in patients with AKT1(E17K)-mutated breast and ovarian cancers. AZD5363 combined with AZD4547 showed tumor regression in bladder cancer xenografts with AKT1(E17K) and FGFR3(Y373C) mutations.

Conclusions:

  • Tumors harboring the AKT1(E17K) mutation represent a validated therapeutic target for AKT inhibitors.
  • AKT inhibitors demonstrate clinical activity in patients with AKT1(E17K)-mutated cancers.
  • Combination therapy with other targeted agents may be necessary for tumors with multiple oncogenic driver mutations, such as AKT1(E17K) and FGFR3(Y373C).

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K